Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies

References

• Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634–641. doi:10.1182/blood-2003-06-2095.
   PubMed Web of Science ®Google Scholar
• Wilson W1, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685–2693. doi:10.1182/blood.V99.8.2685.
   PubMed Web of Science ®Google Scholar
• Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, Moorman AV, Wade R. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014;15:809–818. doi:10.1016/S1470-2045(14)70243-8.
   PubMed Web of Science ®Google Scholar
• Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24:265–284. doi:10.1038/leu.2009.257.
   PubMed Web of Science ®Google Scholar
• Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, Reaman GH, Carroll WL. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30:1663–1669. doi:10.1200/JCO.2011.37.8018.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242. doi:10.1056/NEJMoa011795.
   PubMed Web of Science ®Google Scholar
• : Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–116. doi:10.1016/S1470-2045(08)70002-0.
   PubMed Web of Science ®Google Scholar
• Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, et al. Rituximab in B-lineage adult acute lymphoblastic Leukemia. N Engl J Med. 2016;375:1044–1053. doi:10.1056/NEJMoa1605085.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944–950. doi:10.1182/blood-2006-05-018192.
   PubMed Web of Science ®Google Scholar
• Oriol A, Vives S, Hernandez-Rivas JM, Tormo M, Heras I, Rivas C, Bethencourt C, Moscardo F, Bueno J, Grande C, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010;95:589–596. doi:10.3324/haematol.2009.014274.
   PubMed Web of Science ®Google Scholar
• Tavernier E, Boiron J-M, Huguet F, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21:.1907–1914. doi:10.1038/sj.leu.2404824.
   PubMed Web of Science ®Google Scholar
• Fielding AK. Current therapeutic strategies in adult acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2011;25:1255–1279, viii. doi:10.1016/j.hoc.2011.09.008.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760–3767. doi:10.1182/blood-2005-04-1623.
   PubMed Web of Science ®Google Scholar
• Brüggemann M, Raff T, Flohr T, Gökbuget N, Nakao M, Droese J, Lüschen S, Pott C, Ritgen M, Scheuring U, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116–1123. doi:10.1182/blood-2005-07-2708.
   PubMed Web of Science ®Google Scholar
• Farahat N, Morilla A, Owusu-Ankomah K, Morilla R, Pinkerton CR, Treleaven JG, Matutes E, Powles RL, Catovsky D. 1998. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry. Br J Haematol. 101:158–164. doi:10.1046/j.1365-2141.1998.00675.x.
   PubMed Web of Science ®Google Scholar
• Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, Wood BL, Kelloff GJ, Jessup JM, Radich JP. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic Leukemia: a meta-analysis. JAMA Oncol. 2017;3:.e170580. doi:10.1001/jamaoncol.2017.0580.
   PubMed Web of Science ®Google Scholar
• Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Borlenghi E, Pogliani EM, Di Bona E, Cassibba V, et al. Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. Blood Cancer J. 2014;4:e225. doi:10.1038/bcj.2014.48.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Kneba M, Raff T, Trautmann H, Bartram C-R, Arnold R, Fietkau R, Freund M, Ganser A, Ludwig W-D, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120:1868–1876. doi:10.1182/blood-2011-09-377713.
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Bargou R, Rüttinger D, Kufer P, Baeuerle PA, Zugmaier G. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma. 2009;50:886–891. doi:10.1080/10428190902943077.
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther. 2012;136:334–342. doi:10.1016/j.pharmthera.2012.07.013.
   PubMed Web of Science ®Google Scholar
• Oak E, Bartlett NL. Blinatumomab for the treatment of B-cell lymphoma. Expert Opin Investig Drugs. 2015;24:715–724. doi:10.1517/13543784.2015.1021415.
   PubMed Web of Science ®Google Scholar
• Otero DC, Rickert RC. 2003. CD19 function in early and late B cell development. II. CD19 facilitates the pro-B/pre-B transition. J Immunol. 171:5921–5930. doi:10.4049/jimmunol.171.11.5921.
   PubMed Web of Science ®Google Scholar
• Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, Noppeney R, Hess G, Kallert S, Mackensen A, et al. Bispecific T-Cell Engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-hodgkin Lymphoma: final results from a phase I study. J Clin Oncol. 2016;34:.1104–1111. doi:10.1200/JCO.2014.59.1586.
   PubMed Web of Science ®Google Scholar
• Viardot A, Goebeler M-E, Hess G, Neumann S, Pfreundschuh M, Adrian N, Zettl F, Libicher M, Sayehli C, Stieglmaier J, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127:1410–1416. doi:10.1182/blood-2015-06-651380.
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst H-A, Raff T, Viardot A, Schmid M, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493–2498. doi:10.1200/JCO.2010.32.7270.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler M-E, Klinger M, Neumann SA, Horst HA, Raff T, Viardot A, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120:5185–5187. doi:10.1182/blood-2012-07-441030.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst H-A, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522–1531. doi:10.1182/blood-2017-08-798322.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Zugmaier G, Klinger M, Kufer P, Stelljes M, Viardot A, Horst HA, Neumann S, Brüggemann M, Ottmann OG, et al. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica. 2017;102:e132–e135. doi:10.3324/haematol.2016.153957.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, Viardot A, Marks R, Diedrich H, Faul C, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134–4140. doi:10.1200/JCO.2014.56.3247.
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Gokbuget N, Klinger M, Viardot A, Stelljes M, Neumann S, Horst H-A, Marks R, Faul C, Diedrich H, et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126:2578–2584. doi:10.1182/blood-2015-06-649111.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57–66. doi:10.1016/S1470-2045(14)71170-2.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, Doubek M, Fielding AK, Giebel S, Haddad V, et al. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J. 2016;6:e473. doi:10.1038/bcj.2016.84.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J-M, Wei A, Dombret H, Foà R, Bassan R, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic Leukemia. N Engl J Med. 2017;376:836–847. doi:10.1056/NEJMoa1609783.
   PubMed Web of Science ®Google Scholar
• Topp MS, Zimmerman Z, Cannell P, Dombret H, Maertens J, Stein A, Franklin J, Tran Q, Cong Z, Schuh AC. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood. 2018;131:2906–2914. doi:10.1182/blood-2017-09-804658.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Boissel N, Chevallier P, Ottmann O, Gökbuget N, Topp MS, Fielding AK, Rambaldi A, Ritchie EK, Papayannidis C, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic Leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35:1795–1802. doi:10.1200/JCO.2016.69.3531.
   PubMed Web of Science ®Google Scholar
• von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O’Brien MM, Brethon B, Bhojwani D, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic Leukemia. J Clin Oncol. 2016;34:4381–4389. doi:10.1200/JCO.2016.67.3301.
   PubMed Web of Science ®Google Scholar
• Stein AS, Larson RA, Schuh AC, Stevenson W, Lech-Maranda E, Tran Q, Zimmerman Z, Kormany W, Topp MS. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Adv. 2018;2:1522–1531. doi:10.1182/bloodadvances.2018019034.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19:240–248. doi:10.1016/S1470-2045(18)30011-1.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Su Y, Jabbour EJ, Bhattacharyya H, Yan E, Cappelleri JC, Marks DI. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 2018;124:2151–2160. doi:10.1002/cncr.31317.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory philadelphia chromosome-negative acute lymphoblastic Leukemia: A phase 2 clinical trial. JAMA Oncol. 2018;4:230–234. doi:10.1001/jamaoncol.2017.2380.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O’Brien S, Wang K, Wang T, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016;375:740–753. doi:10.1056/NEJMoa1509277.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119:2728–2736. doi:10.1002/cncr.28136.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13:403–411. doi:10.1016/S1470-2045(11)70386-2.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509–1518. doi:10.1056/NEJMoa1215134.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439–448. doi:10.1056/NEJMoa1709866.
   PubMed Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic Leukemia. N Engl J Med. 2018;378:449–459. doi:10.1056/NEJMoa1709919.
   PubMed Web of Science ®Google Scholar
• Uy N, Nadeau M, Stahl M, Zeidan AM. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia. J Blood Med. 2018;9:67–74. doi:10.2147/JBM.S136575.
   PubMed Web of Science ®Google Scholar
• The quest for off-the-shelf CAR T cells. Cancer Discov. 2018;8:787–788. doi:10.1158/2159-8290.CD-ND2018-005.
   PubMed Web of Science ®Google Scholar
• Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;125:242–248. doi:10.1182/blood-2014-08-597914.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516. doi:10.1056/NEJMoa1306220.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, Verhoef G, Linton K, Thieblemont C, Vitolo U, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28:2169–2178. doi:10.1093/annonc/mdx289.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–1018. doi:10.1056/NEJMoa1314583.
   PubMed Web of Science ®Google Scholar
• Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin Lymphoma. J Clin Oncol. 2017;35:826–833. doi:10.1200/JCO.2016.70.4320.
   PubMed Web of Science ®Google Scholar
• de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede SH, Nolan C, Petrich AM,  et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase 1b dose-finding study. Ann Oncol. 2018. doi:10.1093/annonc/mdy256.
   Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary Results of a phase Ib study. J Clin Oncol. 2016;34:2698–2704. doi:10.1200/JCO.2015.65.9789.
   PubMed Web of Science ®Google Scholar
• Trneny M, Verhoef G, Dyer MJ, Ben Yehuda D, Patti C, Canales M, Lopez A, Awan FT, Montgomery PG, Janikova A, et al. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica. 2018;103:1351–1358. doi:10.3324/haematol.2017.168401.
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16: 704–715. doi:10.1016/S1470-2045(15)70128-2.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540–549. doi:10.1200/JCO.2014.56.2025.
   PubMed Web of Science ®Google Scholar